Suprelorin 4.7mg implant for dogs (pack of 2)

Suprelorin 4.7mg Implant For Dogs ( 2 Pack)

Suprelorin is a desexing implant for male dogs that is both effective and reversible. It is ideal for situations where owners do not want their dogs to have puppies but may want to breed from them in the future. Suprelorin works by controlling the secretion of fertility hormones with the active substance deslorelin. This results in a decrease in the production of testosterone which eventually leads to a lack of interest in mating behaviour. The implant is inserted under the skin on the back of the dog's neck and will provide contraception for up to 6 months. If you are considering using Suprelorin as your dog’s contraception method, please talk to your veterinarian first. They will be able to advise you on the best course of treatment for your individual pet.

How To Buy Suprelorin For Dogs

Suprelorin is a prescription-only medication and a refrigerated product. This means that before you complete your purchase you are required to upload a prescription through our online portal. After our team has confirmed you've ordered the right medication for your dog we can send out your order. It's a simple process that means you can buy Suprelorin dog medication online instead of going to your vet every month.

How To Use Suprelorin For Dogs

The recommended dose is one implant per dog, irrespective of the size of the dog. Disinfection of the implantation site should be undertaken prior to implantation to avoid the introduction of infection. If the hair is long, a small area should be clipped, if required. Insert the implant under the skin on the back of the dog's neck. Repeat administration every six months to maintain efficacy.

Target species

Dogs (male).

Indications for use

For the induction of temporary infertility in healthy, entire, sexually mature male dogs for up to at least 6 months. Insert one implant per dog, irrespective of size.

Contra-indications

None

Special warnings for each target species

Infertility is achieved from 6 weeks up to at least 6 months after initial treatment. Treated dogs should therefore still be kept away from bitches on heat within the first six weeks after initial treatment. One out of 75 dogs treated with the product during clinical trials mated and tied with a bitch on heat within six months of implantation, but this did not result in pregnancy. Should a treated dog mate with a bitch between six weeks and six months after treatment, appropriate measures should be taken to rule out the risk of pregnancy. Any mating that occurs more than six months after the administration of the product may result in pregnancy. However, it is not necessary to keep bitches away from treated dogs following subsequent implantations, provided that the product is administered every six months. The ability of dogs to sire offspring following their return to normal plasma testosterone levels, after the administration of the product, has not been investigated. With respect to testosterone levels (an established surrogate marker of fertility), during clinical trials more than 80 % of dogs administered one or more implants, returned to normal plasma testosterone levels (≥0.4 ng/ml) within 12 months of implantation. Ninety-eight percent of dogs returned to normalplasma testosterone levels within 18 months of implantation. However, data demonstrating the complete reversibility of clinical effects (reduced testicular size, reduced ejaculation volume, reduced sperm count and reduced libido) including fertility after six months, or repeated implantation, are limited. During clinical trials, most of the smaller size dogs (<10 kg) maintained suppressed levels of testosterone for more than 12 months following implantation. For very large dogs (>40 kg), data are limited but duration of testosterone suppression was comparable to that seen in medium and large dogs. The use of the product in dogs of less than 10 kg or more than 40 kg bodyweight, therefore, should be subject to a risk/benefit assessment performed by the veterinarian. Surgical or medical castration might have unexpected consequences (i.e. improvement or worsening) on aggressive behaviour. Thus, dogs with sociopathic disorders and showing episodes of intra-specific (dog to dog) and/or inter-specific (dog to another species) aggressions should not be castrated either surgically or with the implant.

Special precautions for use

Special precautions for use in animals

The use of the product in pre-pubertal dogs has not been investigated. It is therefore recommended that dogs should be allowed to reach puberty before treatment with the product is initiated. Data demonstrate that treatment with the product will reduce the libido of the dog, but other behavioural changes (e.g. male-associated aggression) have not been investigated. Special precautions to be taken by the person administering the veterinary medicinal product to animals Pregnant women should not administer the product. Another GnRH analogue has been shown to be foetotoxic in laboratory animals. Specific studies to evaluate the effect of deslorelin when administered during pregnancy have not been conducted. Although skin contact with the product is unlikely, should this occur, wash the exposed area immediately, as GnRH analogues may be absorbed through the skin. When administering the product, take care to avoid accidental self-injection by ensuring that animals are suitably restrained and the application needle is shielded until the moment of implantation. In case of accidental self-injection, seek medical advice immediately, with a view to having the implant removed. Show the package leaflet or the label to the physician.

Adverse reactions

Moderate swelling at the implant site may be observed for 14 days. Histologically, mild local reactions with chronic inflammation of the connective tissue and some capsule formation and collagen deposition have been seen at 3 months after administration. A significant decrease in testicle size will be seen during the treatment period. In very rare cases, a testicle may be able to ascend the inguinal ring. In very rare cases (<0.01%) there has been transitory increased sexual interest, increased testicle size and testicular pain immediately after implantation. These signs resolved without treatment. During the treatment period, rare clinical effects (> 0.01% to < 0.1%) have been reported: hair coat disorders (e.g. hair loss, alopecia, hair modification), urinary incontinence, down-regulation associated signs (e.g. decrease in testicle size, reduced activity). In very rare cases (<0.01%), a transient behavioural change has been reported with the development of aggression (see section on "Special Warnings for Each Target Species").

Use during pregnancy, lactation or lay

Interactions